Clinical Trial Update: A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing ranibizumab to sham for macular edema caused by central retinal vein occlusion; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Aleris Helse | Conditions: Central Retinal Vein Occlusion, Macular Edema | Phase 3 | Status: COMPLETED